ERresQ

We have identified compounds that mimic the action of the neurotrophic factors MANF and CDNF, central regulators of cellular stress, survival, inflammation, and immune response. Our repurposed assets ERQ-01, ERQ-03, and ERQ-04, along with a new chemical entity ERQ-02, specifically target injured, stressed cells, thereby minimizing side effects. Our therapeutics will treat diabetes, Parkinson’s disease and amyotrophic lateral sclerosis (ALS) by protecting cells from death, regulating protein folding and reducing inflammation.